Cyclic-GMP-Elevating Agents Suppress Polyposis in Apc^Min mice by Targeting the Preneoplastic Epithelium.

Sharman SK, Islam BN, Hou Y, Singh N, Berger FG, Sridhar S, Yoo W, Browning DD

Cancer prevention research (Philadelphia, Pa.)4 Jan 2018Cited by 29 (Europe PMC)

PMID29301746PMCIDPMC5811348DOI10.1158/1940-6207.capr-17-0267PepBankPUB-29301746

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In Apc Min/+ mice, linaclotide significantly reduced polyp number per mouse by 67%.
In plain wordsIn mice with an intestinal cancer model, linaclotide reduced polyp numbers by 67%.
Peptide
Linaclotide
Outcome
DecreasePolyp number
Study
mousen: not reported in source
Apc Min/+ intestinal cancer model
Outcome group
Tumor growth · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Treatment of Apc^Min/+ mice with the receptor guanylyl-cyclase C (GCC) agonist linaclotide, or the phosphodiesterase-5 (PDE5) inhibitor sildenafil, significantly reduced the number of polyps per mouse (67% and 50%, respectively).
1 context sentence(design, population, supporting numbers)
Summary · context
This study has tested the effect of cGMP-elevating agents on tumorigenesis in the Apc^Min^/+ mouse model of intestinal cancer.
Report a problemFND-2930174601
02AnimalAnimal study (in vivo)Efficacy outcome
In Apc Min/+ mice, linaclotide did not affect mean polyp size.
In plain wordsIn mice with an intestinal cancer model, linaclotide did not change mean polyp size.
Peptide
Linaclotide
Outcome
No significant changeMean polyp size
Study
mousen: not reported in source
Apc Min/+ intestinal cancer model
Outcome group
Tumor growth · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Neither of the drugs affected mean polyp size, or the rates of apoptosis and proliferation.
2 context sentences(design, population, supporting numbers)
Summary · context
Treatment of Apc^Min/+ mice with the receptor guanylyl-cyclase C (GCC) agonist linaclotide, or the phosphodiesterase-5 (PDE5) inhibitor sildenafil, significantly reduced the number of polyps per mouse (67% and 50%, respectively).
Summary · context
This study has tested the effect of cGMP-elevating agents on tumorigenesis in the Apc^Min^/+ mouse model of intestinal cancer.
Report a problemFND-2930174602
03AnimalAnimal study (in vivo)Efficacy outcome
In Apc Min/+ mice, linaclotide did not affect apoptosis rates in polyps.
In plain wordsIn mice with an intestinal cancer model, linaclotide did not change cell death rates in polyps.
Peptide
Linaclotide
Outcome
No significant changePolyp apoptosis
Study
mousen: not reported in source
Apc Min/+ intestinal cancer model
Outcome group
Tumor growth · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Neither of the drugs affected mean polyp size, or the rates of apoptosis and proliferation.
2 context sentences(design, population, supporting numbers)
Summary · context
Treatment of Apc^Min/+ mice with the receptor guanylyl-cyclase C (GCC) agonist linaclotide, or the phosphodiesterase-5 (PDE5) inhibitor sildenafil, significantly reduced the number of polyps per mouse (67% and 50%, respectively).
Summary · context
This study has tested the effect of cGMP-elevating agents on tumorigenesis in the Apc^Min^/+ mouse model of intestinal cancer.
Report a problemFND-2930174603
04AnimalAnimal study (in vivo)Efficacy outcome
In Apc Min/+ mice, linaclotide did not affect proliferation rates in polyps.
In plain wordsIn mice with an intestinal cancer model, linaclotide did not change cell growth rates in polyps.
Peptide
Linaclotide
Outcome
No significant changePolyp proliferation
Study
mousen: not reported in source
Apc Min/+ intestinal cancer model
Outcome group
Tumor growth · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Neither of the drugs affected mean polyp size, or the rates of apoptosis and proliferation.
2 context sentences(design, population, supporting numbers)
Summary · context
Treatment of Apc^Min/+ mice with the receptor guanylyl-cyclase C (GCC) agonist linaclotide, or the phosphodiesterase-5 (PDE5) inhibitor sildenafil, significantly reduced the number of polyps per mouse (67% and 50%, respectively).
Summary · context
This study has tested the effect of cGMP-elevating agents on tumorigenesis in the Apc^Min^/+ mouse model of intestinal cancer.
Report a problemFND-2930174604
05AnimalAnimal study (in vivo)Mechanism
In Apc Min/+ mice, linaclotide suppressed proliferation in intestinal mucosa.
In plain wordsIn mice with an intestinal cancer model, linaclotide reduced cell growth in the intestinal lining.
Peptide
Linaclotide
Outcome
DecreaseIntestinal mucosal proliferation
Study
mousen: not reported in source
Apc Min/+ intestinal cancer model
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Administration of either sildenafil or linaclotide suppressed proliferation, and increased both goblet cell numbers and luminal apoptosis in the intestinal mucosa.
1 context sentence(design, population, supporting numbers)
Summary · context
This study has tested the effect of cGMP-elevating agents on tumorigenesis in the Apc^Min^/+ mouse model of intestinal cancer.
Report a problemFND-2930174605
06AnimalAnimal study (in vivo)Mechanism
In Apc Min/+ mice, linaclotide increased goblet cell numbers in intestinal mucosa.
In plain wordsIn mice with an intestinal cancer model, linaclotide increased goblet cell numbers in the intestinal lining.
Peptide
Linaclotide
Outcome
IncreaseIntestinal goblet cell number
Study
mousen: not reported in source
Apc Min/+ intestinal cancer model
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Administration of either sildenafil or linaclotide suppressed proliferation, and increased both goblet cell numbers and luminal apoptosis in the intestinal mucosa.
1 context sentence(design, population, supporting numbers)
Summary · context
This study has tested the effect of cGMP-elevating agents on tumorigenesis in the Apc^Min^/+ mouse model of intestinal cancer.
Report a problemFND-2930174606
07AnimalAnimal study (in vivo)Mechanism
In Apc Min/+ mice, linaclotide increased luminal apoptosis in intestinal mucosa.
In plain wordsIn mice with an intestinal cancer model, linaclotide increased cell death toward the intestinal lumen.
Peptide
Linaclotide
Outcome
IncreaseLuminal apoptosis
Study
mousen: not reported in source
Apc Min/+ intestinal cancer model
Outcome group
Receptor activity and mechanism · Gastrointestinal
Studied dose
Dose not stated
Source sentences
Summary
Administration of either sildenafil or linaclotide suppressed proliferation, and increased both goblet cell numbers and luminal apoptosis in the intestinal mucosa.
1 context sentence(design, population, supporting numbers)
Summary · context
This study has tested the effect of cGMP-elevating agents on tumorigenesis in the Apc^Min^/+ mouse model of intestinal cancer.
Report a problemFND-2930174607

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.